Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,080.00 at Barclays
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price dropped by Barclays from $1,220.00 to $1,080.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Barclays‘s target price indicates a potential upside of 12.23% from the company’s previous close. A number of […]
23 Oct 13:49 · The Markets Daily